Cargando…

Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials

INTRODUCTION: Guidelines recommend clozapine for treatment-resistant schizophrenia. However, meta-analysis of aggregate data (AD) did not demonstrate higher efficacy of clozapine compared with other second-generation antipsychotics but found substantial heterogeneity between trials and variation bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siafis, Spyridon, Schneider-Thoma, Johannes, Hamza, Tasnim, Bighelli, Irene, Dong, Shimeng, Hansen, Wulf-Peter, Davis, John M, Salanti, Georgia, Leucht, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Mental Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945033/ https://www.ncbi.nlm.nih.gov/pubmed/36810167 http://dx.doi.org/10.1136/bmjopen-2022-064504

Ejemplares similares

Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials
por: Schneider-Thoma, Johannes, et al.
Publicado: (2021)

T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS – PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis
por: Feber, Lena, et al.
Publicado: (2023)

Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence
por: Bighelli, Irene, et al.
Publicado: (2020)

M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA – A META-REGRESSION ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials
por: Bighelli, Irene, et al.
Publicado: (2018)

Estimating and visualising the trade-off between benefits and harms on multiple clinical outcomes in network meta-analysis
por: Chiocchia, Virginia, et al.
Publicado: (2023)

Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
por: Siafis, Spyridon, et al.
Publicado: (2023)

S235. MAINTENANCE TREATMENT WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

T6. SECOND GENERATION ANTIPSYCHOTIC DRUGS AND MORTALITY: A META-ANALYSIS OF PLACEBO-CONTROLLED RANDOMISED CONTROLLED TRIALS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
por: Huhn, Maximilian, et al.
Publicado: (2019)

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
por: Huhn, Maximilian, et al.
Publicado: (2022)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders
por: Rodolico, Alessandro, et al.
Publicado: (2022)

Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
por: Wagner, Elias, et al.
Publicado: (2021)

Digital health interventions to improve adherence to oral antipsychotics among patients with schizophrenia: a scoping review
por: Wu, Tao, et al.
Publicado: (2023)

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis
por: Furukawa, Toshi A, et al.
Publicado: (2016)

Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
por: Moncrieff, Joanna, et al.
Publicado: (2019)

Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2022)

The Added Value of Liquid Antipsychotics: The Case of Quetiapine
por: Papazisis, Georgios, et al.
Publicado: (2019)

Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia
por: Siafis, Spyridon, et al.
Publicado: (2022)

Combination treatment with second generation antipsychotics other than clozapine
por: Schmidt-Kraepelin, C.
Publicado: (2021)

Patients’ and psychiatrists’ perspectives on clozapine treatment—a scoping review protocol
por: Jakobsen, Michelle Iris, et al.
Publicado: (2021)

Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis
por: Okhuijsen‐Pfeifer, C., et al.
Publicado: (2018)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis
por: Gutsmiedl, Katharina, et al.
Publicado: (2020)

F214. PSYCHOLOGICAL INTERVENTIONS FOR POSITIVE SYMPTOMS IN SCHIZOPHRENIA: A NETWORK META-ANALYSIS
por: Bighelli, Irene, et al.
Publicado: (2018)

Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol
por: Lopes, Luis Phillipe Nagem, et al.
Publicado: (2023)

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine
por: Siskind, Dan, et al.
Publicado: (2018)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia
por: Jeon, Soo Min, et al.
Publicado: (2022)

Antipsychotic Polypharmacy in Clozapine Resistant Schizophrenia: A Randomized Controlled Trial of Tapering Antipsychotic Co-treatment
por: Repo-Tiihonen, Eila, et al.
Publicado: (2012)

Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
por: Vasiliu, Octavian
Publicado: (2022)

Characterising the evolution of antipsychotic polypharmacy and clozapine prescribing patterns in schizophrenia patients during psychiatric hospitalisations
por: Lagreula, J., et al.
Publicado: (2022)

Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
por: Leucht, Stefan, et al.
Publicado: (2021)

Informing the development of a decision aid: Expectations and wishes from service users and psychiatrists towards a decision aid for antipsychotics in the inpatient setting
por: Müller, Katharina, et al.
Publicado: (2023)

Study protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia
por: Farooq, Saeed, et al.
Publicado: (2022)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3g5cf9oq8cjdd24hqqihov9sv4